再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

已收盘 07-26 16:00:00 EDT

18.86

-0.01

-0.05%

盘后18.86

+0.000.00%

17:09 EDT

最高19.58	最低18.60	成交量76.96万
今开19.18	昨收18.87	日振幅5.19%
总市值18.69亿	流通市值16.86亿	总股本9,912万
成交额1,468万	换手率0.86%	流通股本8,940万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":18.86,"timestamp":1722024000000,"preClose":18.87,"halted":0,"volume":769583,"hourTrading":{"tag":"盘后","latestPrice":18.86,"preClose":18.86,"latestTime":"17:09 EDT","volume":110351,"amount":2081216.66,"timestamp":1722028192412},"delay":0,"floatShares":89396762,"shares":99117547,"eps":-3.496752,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.01,"latestTime":"07-26 16:00:00 EDT","open":19.18,"high":19.58,"low":18.6,"amount":14681365.67432,"amplitude":0.051934,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.496752,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1722240000000},"adr":1,"listingDate":1505880000000,"adjPreClose":18.87,"adrRate":10,"preHourTrading":{"tag":"盘前","latestPrice":19.44,"preClose":18.87,"latestTime":"09:03 EDT","volume":3,"amount":58.240002,"timestamp":1721999007348},"postHourTrading":{"tag":"盘后","latestPrice":18.86,"preClose":18.86,"latestTime":"17:09 EDT","volume":110351,"amount":2081216.66,"timestamp":1722028192412},"volumeRatio":1.579129,"impliedVol":0.3407,"impliedVolPercentile":0.0357},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2454320328","title":"再鼎医药上涨2.17%，报19.28美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2454320328","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454320328?lang=zh_cn&edition=full","pubTime":"2024-07-26 21:46","pubTimestamp":1722001584,"startTime":"0","endTime":"0","summary":"7月26日，再鼎医药(ZLAB)盘中上涨2.17%，截至21:46，报19.28美元/股，成交18.58万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月6日，再鼎医药将于(美东)盘后披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/26214641851530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1574","ZLAB","BK4139","BK4531","BK1161","BK4585","BK4526","BK1588","BK4588","BK4548","09688"],"gpt_icon":0},{"id":"2454887686","title":"再鼎医药：计划于2024年8月7日发布未经审核的中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2454887686","media":"金融界港股","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454887686?lang=zh_cn&edition=full","pubTime":"2024-07-25 20:45","pubTimestamp":1721911500,"startTime":"0","endTime":"0","summary":"金融界7月25日消息，再鼎医药有限公司于2024年8月6日（美国东部时间）/2024年8月7日（香港时间）将审议并批准截至2024年6月30日期间的三个月和六个月的未经审核中期业绩。若这些业绩获得批准，再鼎医药将于2024年8月6日（美国东部时间）/2024年8月7日（香港时间）在香港联合交易所有限公司网站和公司官方网站发布业绩公告。以上数据未经审核。\n\n\r\n            责任编辑：十八","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/25204541808456.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","BK4139","BK4585","BK4526","BK4588","BK4531","BK4548","ZLAB","BK1574","09688","BK1588"],"gpt_icon":0},{"id":"2454608818","title":"南向资金7月24日净卖出再鼎医药4.97万股 连续7日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2454608818","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2454608818?lang=zh_cn&edition=full","pubTime":"2024-07-25 09:31","pubTimestamp":1721871093,"startTime":"0","endTime":"0","summary":"7月24日，南向资金减持再鼎医药4.97万股连续7日减持。截止当日收盘，港股通共持有再鼎医药9702.85万股，占流通股9.73%。再鼎医药近5个交易日上涨3.50%，港股通累计减持282.94万股；近20个交易日上涨3.07%，港股通累计减持370.72万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072509442195584595&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072509442195584595&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","ZLAB","BK1574","09688","BK1588"],"gpt_icon":0},{"id":"2453219147","title":"南向资金7月22日净卖出再鼎医药115.95万股 连续5日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2453219147","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453219147?lang=zh_cn&edition=full","pubTime":"2024-07-23 09:31","pubTimestamp":1721698299,"startTime":"0","endTime":"0","summary":"7月22日，南向资金减持再鼎医药115.95万股连续5日减持。截止当日收盘，港股通共持有再鼎医药9795.86万股，占流通股9.82%。再鼎医药近5个交易日上涨8.01%，港股通累计减持278.72万股；近20个交易日上涨8.01%，港股通累计减持284.28万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072309444595515554&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072309444595515554&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","BK1588","09688","ZLAB"],"gpt_icon":0},{"id":"2453205792","title":"再鼎医药上涨5.14%，报19.62美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2453205792","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453205792?lang=zh_cn&edition=full","pubTime":"2024-07-22 23:36","pubTimestamp":1721662613,"startTime":"0","endTime":"0","summary":"7月22日，再鼎医药(ZLAB)盘中上涨5.14%，截至23:36，报19.62美元/股，成交235.74万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月6日，再鼎医药将于(美东)盘后披露2024财年中报。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/22233641723379.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["ZLAB","BK4548","09688","BK1161","BK4531","BK4585","BK4526","BK4588","BK4139","BK1574","BK1588"],"gpt_icon":0},{"id":"2453792766","title":"再鼎医药盘中异动 急速拉升5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2453792766","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453792766?lang=zh_cn&edition=full","pubTime":"2024-07-22 23:36","pubTimestamp":1721662594,"startTime":"0","endTime":"0","summary":"北京时间2024年07月22日23时36分，再鼎医药股票出现波动，股价快速上涨5.04%。截至发稿，该股报19.60美元/股，成交量11.4018万股，换手率0.12%，振幅4.93%。机构评级方面，在所有12家参与评级的机构中，92%的券商给予买入建议，8%的券商给予持有建议，无券商给予卖出建议。再鼎医药股票所在的生物技术行业中，整体涨幅为0.37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407222336359681eece&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202407222336359681eece&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4531","BK4526","ZLAB","BK4548","BK4139"],"gpt_icon":0},{"id":"2453764424","title":"年内第三款产品获批，再鼎医药艾加莫德皮下剂型前景如何","url":"https://stock-news.laohu8.com/highlight/detail?id=2453764424","media":"医药经济报","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453764424?lang=zh_cn&edition=full","pubTime":"2024-07-22 20:07","pubTimestamp":1721650079,"startTime":"0","endTime":"0","summary":"近日，再鼎医药和argenx公司宣布艾加莫德皮下注射制剂的新药上市申请已获中国国家药监局批准，与常规治疗药物联合，用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力患者。艾加莫德成为国内首个获批治疗gMG的皮下注射制剂。此外，艾加莫德皮下注射治疗表现出与3期ADAPT研究一致的安全性。随着其适应症的不断扩展，艾加莫德有望成为新一代的“重磅炸弹”药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072220125895e8395e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024072220125895e8395e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ZLAB","BK4548","BK4139","BK4588","BK4531","BK4526","BK4585"],"gpt_icon":0},{"id":"2452493778","title":"南向资金7月18日净卖出再鼎医药70.34万股 连续3日减持","url":"https://stock-news.laohu8.com/highlight/detail?id=2452493778","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452493778?lang=zh_cn&edition=full","pubTime":"2024-07-19 09:31","pubTimestamp":1721352700,"startTime":"0","endTime":"0","summary":"7月18日，南向资金减持再鼎医药70.34万股连续3日减持。截止当日收盘，港股通共持有再鼎医药9915.45万股，占流通股9.94%。港股通减持金额前五个股分别为香港交易所、中国神华、中国宏桥、理想汽车-W、东岳集团。再鼎医药近5个交易日上涨12.69%，港股通累计减持147.24万股；近20个交易日上涨5.30%，港股通累计减持191.61万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909435595d9acbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024071909435595d9acbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","ZLAB","BK1588","09688","BK1574"],"gpt_icon":0},{"id":"2452127200","title":"再鼎医药(09688)上涨5.04%，报15.0元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2452127200","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452127200?lang=zh_cn&edition=full","pubTime":"2024-07-18 14:35","pubTimestamp":1721284548,"startTime":"0","endTime":"0","summary":"7月18日，再鼎医药(09688)盘中上涨5.04%，截至14:35，报15.0元/股，成交4127.84万元。再鼎医药有限公司主要业务是研发和销售针对肿瘤、自身免疫性疾病、感染性疾病和中枢神经系统疾病的创新药物，以满足全球患者的医疗需求。关键经营数据方面，公司以其强大的研发能力和全球化运营策略，致力于成为全球领先的生物制药公司。截至2024年一季报，再鼎医药营业总收入6.18亿元、净利润-3.79亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/07/18143541642834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4139","ZLAB","BK4585","BK1161","BK4531","BK4588","09688","BK4526","BK4548","BK1588","BK1574"],"gpt_icon":0},{"id":"2452454491","title":"港股异动 | 再鼎医药(09688)再涨超3% 近日与argenx宣布艾加莫德皮下注射国内获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2452454491","media":"智通财经","labels":["Product Release"],"top":-1,"share":"https://www.laohu8.com/m/news/2452454491?lang=zh_cn&edition=full","pubTime":"2024-07-18 09:44","pubTimestamp":1721267063,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药(09688)再涨超3%，截至发稿，涨3.50%，报14.78港元，成交额931.22万港元。消息面上，近日，再鼎医药和argenx宣布，艾加莫德皮下注射制剂获国家药监局批准上市，与常规治疗药物联合，用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力(gMG)患者。这也是国内首个获批治疗全身型重症肌无力的皮下注射制剂。浦银国际此前研报认为，维持再鼎医药“买入”评级，将2024E、2025E收入分别上调7.5%、3.1%，主要由于上调艾加莫德和即将获批新药物收入导致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1152417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4548","09688","BK1588","BK4531","BK4585","HSCEI","BK4139","BK1574","HSTECH","YANG","BK1161","ZLAB","BK4588","BK4526"],"gpt_icon":1},{"id":"2451937583","title":"港股异动 | 再鼎医药(09688)午后涨超4% 艾加莫德皮下注射国内获批 用于治疗全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2451937583","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451937583?lang=zh_cn&edition=full","pubTime":"2024-07-16 13:35","pubTimestamp":1721108137,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药(09688)午后涨超4%，截至发稿，涨3.64%，报14.24港元，成交额2988.5万港元。消息面上，再鼎医药午间宣布，国家药品监督管理局已经批准了卫力迦®（艾加莫德皮下注射，1000mg（5.6ml）/瓶）的生物制品上市许可申请，与常规治疗药物联合，用于治疗乙酰胆碱受体（AChR）抗体阳性的成人全身型重症肌无力（gMG）患者。浦银国际此前指出，艾加莫德增长势头愈发强劲，维持全年七千万美元销售指引。该行表示，随着持续放量及适应症拓展，艾加莫德有望为再鼎医药实现其战略目标（2023-2028年均复合收入增长率超过50%）提供强有力的驱动。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1151391.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07226","BK1588","ZLAB","BK4139","BK4526","HSTECH","09688","BK4588","HSCEI","BK4548","BK1574","BK4531","BK1161","YANG","BK4585"],"gpt_icon":0},{"id":"2451937790","title":"再鼎医药和argenx宣布卫力迦®（艾加莫德皮下注射）国内获批用于治疗全身型重症肌无力","url":"https://stock-news.laohu8.com/highlight/detail?id=2451937790","media":"美通社","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451937790?lang=zh_cn&edition=full","pubTime":"2024-07-16 13:33","pubTimestamp":1721107980,"startTime":"0","endTime":"0","summary":"在全球3 期临床研究ADAPT-SC 中，艾加莫德皮下注射表现出和艾加莫德静脉输注一致的临床获益和安全性。\" 艾加莫德皮下注射的获批是基于全球3期ADAPT-SC研究的阳性结果。艾加莫德是首个获批的FcRn拮抗剂，用于治疗乙酰胆碱受体抗体阳性的成人全身型重症肌无力患者。关于argenxargenx是一家全球性的免疫学公司，致力于改善严重自身免疫性疾病患者的生活质量。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4462332_ZH62332_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["ZLAB","BK4548","09688","BK1161","BK4531","BK4585","BK4526","BK4588","BK4139","BK1574","BK1588"],"gpt_icon":0},{"id":"2450372033","title":"美国研究综述：波士顿啤酒公司、Inter Parfums、Netflix","url":"https://stock-news.laohu8.com/highlight/detail?id=2450372033","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450372033?lang=zh_cn&edition=full","pubTime":"2024-07-12 15:46","pubTimestamp":1720770376,"startTime":"0","endTime":"0","summary":"    路透7月12日 - 华尔街证券分析师周五修订了对波士顿啤酒公司、Inter Parfums 和 Netflix 等几家美国上市公司的评级和目标价。亮点             * 波士顿啤酒公司  ：Piper Sandler 将该公司的目标价从 350 美元下调至 344 美元              * Inter Parfums Inc   ：杰富瑞将其评级从 \"持有 \"上调至 \"买入              * Netflix Inc   ：摩根大通将目标价从650美元上调至750美元              * Smurfit Westrock   ：摩根大通将该股列入分析师关注名单              * Vita Coco Company Inc   ：Piper Sandler将其评级从 \"增持 \"下调至 \"中性\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WES","PTLO","LU1861220207.SGD","BK4146","WPC","IPG","SW","NFLX","CPT","WEX","LU0234572021.USD","BK4209","ZLAB","BK4201","LU1153585028.USD","SG9999004303.SGD","KALV","BK4550","EL","BK4127","BK4566","BK4548","SAGE","IPAR","BK4108","LU2098885051.SGD","NKE","OXY","SG9999001077.SGD","BK4009","YMAB","BK4558","CAG","MEI","LU2360107671.USD","LU1046421795.USD","BSVN","CPAY","IE00B19Z8W00.USD","SCHW","SAM","BK4177","COCO","LU0266013472.USD","LU0786609619.USD","PNTG","LU1303367103.USD","LU1861217088.USD","PEP","IDYA"],"gpt_icon":0},{"id":"2450393615","title":"再鼎医药上涨5.1%，报17.92美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450393615","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450393615?lang=zh_cn&edition=full","pubTime":"2024-07-12 00:35","pubTimestamp":1720715732,"startTime":"0","endTime":"0","summary":"7月12日，再鼎医药(ZLAB)盘中上涨5.1%，截至00:35，报17.92美元/股，成交235.35万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月5日，再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/12003541527432.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1161","BK1588","BK4585","BK4526","BK4531","BK4588","ZLAB","BK4548","09688","BK1574","BK4139"],"gpt_icon":0},{"id":"2450339390","title":"再鼎医药盘中异动 股价大涨5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450339390","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450339390?lang=zh_cn&edition=full","pubTime":"2024-07-12 00:35","pubTimestamp":1720715726,"startTime":"0","endTime":"0","summary":"北京时间2024年07月12日00时35分，再鼎医药股票出现异动，股价快速上涨5.10%。截至发稿，该股报17.92美元/股，成交量13.2931万股，换手率0.13%，振幅4.69%。再鼎医药股票所在的生物技术行业中，整体涨幅为0.05%。消息层面，截至00时35分，《美银证券维持再鼎医药买入评级，下调目标价至21美元》资讯为影响再鼎医药的重要信息。该信息摘要如下：美银证券分析师David Li维持$再鼎医药 $买入评级，并将目标价从25美元下调至21美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712003526af91e2d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712003526af91e2d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","ZLAB","BK4588","BK4531","BK4548","BK4139","BK4526"],"gpt_icon":0},{"id":"2449260195","title":"再鼎医药上涨2.32%，报17.62美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260195","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449260195?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:32","pubTimestamp":1720186364,"startTime":"0","endTime":"0","summary":"7月5日，再鼎医药(ZLAB)开盘上涨2.32%，截至21:32，报17.62美元/股，成交7.64万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月5日，再鼎医药将披露2024财年中报。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/05213241410307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1161","BK4526","ZLAB","BK1588","09688","BK1574","BK4139","BK4548","BK4585","BK4588","BK4531"],"gpt_icon":0},{"id":"2448748691","title":"再鼎医药上涨2.07%，报17.73美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448748691","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448748691?lang=zh_cn&edition=full","pubTime":"2024-07-03 22:15","pubTimestamp":1720016157,"startTime":"0","endTime":"0","summary":"7月3日，再鼎医药(ZLAB)盘中上涨2.07%，截至22:15，报17.73美元/股，成交66.96万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月5日，再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/03221541361130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4531","BK4588","BK4139","BK1161","BK1574","09688","BK4585","BK4548","ZLAB","BK4526","BK1588"],"gpt_icon":0},{"id":"2448157278","title":"再鼎医药下跌2.08%，报16.93美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2448157278","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448157278?lang=zh_cn&edition=full","pubTime":"2024-07-02 22:04","pubTimestamp":1719929042,"startTime":"0","endTime":"0","summary":"7月2日，再鼎医药(ZLAB)盘中下跌2.08%，截至22:04，报16.93美元/股，成交84.02万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月5日，再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/07/02220441335512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK1161","BK4139","BK4585","BK4526","BK4588","BK4531","BK4548","ZLAB","BK1574","09688","BK1588"],"gpt_icon":0},{"id":"2448615889","title":"再鼎医药(09688)：授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2448615889","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448615889?lang=zh_cn&edition=full","pubTime":"2024-07-02 19:50","pubTimestamp":1719921010,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，于2024年7月1日(美国东部时间)，公司根据2024年股权激励计划向1名承授人授出可认购合共600股美国存托股份的购股权并向1名承授人涉及合共900股美国存托股份的受限制股份单位;以及公司根据2024年股权激励计划向杜莹博士授出涉及合共7.2万股美国存托股份的受限制股份单位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1144638.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4531","BK4588","BK4526","BK1574","BK4139","09688","BK4585","BK4548","BK1588","BK1161","ZLAB"],"gpt_icon":0},{"id":"2446687683","title":"再鼎医药下跌2.11%，报17.15美元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2446687683","media":"金融界","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2446687683?lang=zh_cn&edition=full","pubTime":"2024-06-28 23:31","pubTimestamp":1719588708,"startTime":"0","endTime":"0","summary":"6月28日，再鼎医药(ZLAB)盘中下跌2.11%，截至23:31，报17.15美元/股，成交441.41万美元。财务数据显示，截至2024年03月31日，再鼎医药收入总额8714.9万美元，同比增长38.78%；归母净利润-5347.1万美元，同比减少8.8%。大事提醒：8月5日，再鼎医药将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://usstock.jrj.com.cn/2024/06/28233141275628.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_highlight","symbols":["BK4548","BK4588","BK4526","BK4585","ZLAB","BK1574","BK4139","BK4531","09688","BK1588","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0037},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.186},{"period":"6month","weight":-0.1702},{"period":"1year","weight":-0.3919},{"period":"ytd","weight":-0.3095}],"compareEarnings":[{"period":"1week","weight":-0.0258},{"period":"1month","weight":-0.0118},{"period":"3month","weight":0.0593},{"period":"6month","weight":0.1046},{"period":"1year","weight":0.182},{"period":"ytd","weight":0.1328}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zai Lab Ltd是一家主要从事生物制药的控股公司该公司致力于发现或许可、开发和商业化专有疗法，以解决中国市场中大量未满足医疗需求的领域，包括肿瘤学、自身免疫和传染病。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物。其中包括Niraparib（ZL-2306）、ZL-2103和ZL-1101等。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.113311},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.022208},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.101183},{"month":4,"riseRate":0.428571,"avgChangeRate":0.026877},{"month":5,"riseRate":0.571429,"avgChangeRate":0.03934},{"month":6,"riseRate":0.428571,"avgChangeRate":0.063316},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.007249},{"month":8,"riseRate":0.666667,"avgChangeRate":0.013621},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.113197},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.064295},{"month":11,"riseRate":0.714286,"avgChangeRate":0.168146},{"month":12,"riseRate":0.571429,"avgChangeRate":-0.005362}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}